<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) are hematologically diverse hematopoietic stem cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> primarily affecting older individuals </plain></SENT>
<SENT sid="1" pm="."><plain>The incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in the United States is estimated at 3.3 per 100 000; however, evidence suggests underreporting of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> to centralized <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registries </plain></SENT>
<SENT sid="2" pm="."><plain>Contrary to clinical recommendations, registry guidelines from 2001-2010 required the capture of only one <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in the myeloid lineage and did not require blood count (BC) or bone marrow (BM) biopsy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> confirmation </plain></SENT>
<SENT sid="3" pm="."><plain>To address these potential limitations, we constructed 4 claims-based algorithms to assess <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> incidence, applied the algorithms to the 2000-2008 Surveillance Epidemiology and End Results (SEER)-Medicare database, and assessed algorithm validity using SEER-registered <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases </plain></SENT>
<SENT sid="4" pm="."><plain>Each algorithm required one or more <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> claims and accounted for recommended diagnostic services during the year before the first claim: 1+, 2+, 2 + BC, and 2 + BCBM (ordered by sensitivity) </plain></SENT>
<SENT sid="5" pm="."><plain>Each had moderate sensitivities (78.05%-92.90%) and high specificities (98.49%-99.84%), with the 2 + BCBM algorithm demonstrating the highest specificity </plain></SENT>
<SENT sid="6" pm="."><plain>Based on the 2 + BCBM algorithm, the annual incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is 75 per 100 000 persons 65 years or older-much higher than the 20 per 100 000 reported by SEER using the same sample </plain></SENT>
</text></document>